Skip to content

A single prospective randomized controlled clinical trial of antiepileptic drug regimen for glioma patients with non-preoperative epilepsy

A single prospective randomized controlled clinical trial of antiepileptic drug regimen for glioma patients with non-preoperative epilepsy

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000030052
Enrollment
Unknown
Registered
2020-02-21
Start date
2020-05-01
Completion date
Unknown
Last updated
2020-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioma related epilepsy

Interventions

Group 1:take levetiracetam for 1 week
Group 2:take levetiracetam for 4 weeks

Sponsors

Beijing Tiantan Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. The patient was diagnosed as primary glioma by imaging. Before the tumor resection in our hospital, they had no history of brain trauma, operation and auxiliary treatment (such as radiotherapy, chemotherapy, etc., except for the treatment of drug-induced intracranial pressure reduction); 2. Aged > 18 years; 3. Random grouping within 7 days after the operation.

Exclusion criteria

Exclusion criteria: 1. Postoperative pathological result shows: non-glioma (WHO grade II-IV) [According to the pathological diagnosis standard of nervous system tumor (WHO, 2016 version)]; 2. No standardized postoperative radiotherapy and chemotherapy according to the pathological results; 3. Those allergic to levetiracetam; 4. For patients with primary epilepsy, status epileptics, have a long-term history of AED drugs, long-term use of addictive drugs such as some sedative pain drugs, antipsychotic drugs, etc., have a combination of other diseases such as dementia or mental state abnormality; 5. Patients with liver and kidney dysfunction, coagulation dysfunction and other surgical contraindications; 6. Pregnant and lactating patients; 7. The patients considered by the researchers are not suitable for the study.

Design outcomes

Primary

MeasureTime frame
Engel standard;

Countries

China

Contacts

Public ContactLei Wang
wangleitiantan@163.com+86 13581705966

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026